Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

This paper presents a small-signal model of a grid-feeding inverter incorporating dynamics associated with the current regulator, pulse width modulator, phase-locked loop, and interconnecting filter.